# Tridek-One

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tridek-one

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.tridekone.com
- Total disclosed funding: $3.4M
- Latest round: Series A (Nov 26, 2018)
- Investors on record: 2

## About

Based in Paris, France, and founded in 2018, Tridek-One SAS is a biotechnology startup focused on the research and development of CD31 agonist molecules, intended for restoring the immune balance in patients suffering from auto-immune diseases. The company was founded by Giuseppina Caligiuri, and Antonino Nicoletti at INSERM (Paris, France), and in 2019, the firm raised EUR 3 million in a funding round led by AdBio partners, and Advent Life Sciences. In September 2022, Tridek-One Therapeutics raised EUR 16 million in venture funding led by BB Pureos Bioventures, Bioqube Ventures, and Bpifrance. As of October 2022, the company is being led by its Chief Executive Officer, Laurence de Schoulepnikoff.

Tridek-One SAS develops novel CD31 (also known as PECAM-1) checkpoint agonists that are capable of restoring the inhibitory activity of CD31 in immune and endothelial cells, by targeting activated cells and exerting a regulatory effect. The CD31 agonist molecules can rebalance the immune system without immunosuppression, which makes it a potential target for autoimmune and inflammatory disorders.

The company intends to use the September 2022 funding to further develop its product, and conduct more clinical tests.

## Funding rounds

- Series A, Nov 26, 2018, $3.4M — Advent Life Sciences, AdBio Partners

## Investors

- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A
- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Series A